cell lines mm 1 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
97
Structured Review
ATCC
cell lines mm 1
Cell Lines Mm 1, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1083 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell lines mm 1/product/ATCC
Average 97 stars, based on 1083 article reviews
Cell Lines Mm 1, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1083 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell lines mm 1/product/ATCC
Average 97 stars, based on 1083 article reviews
cell lines mm 1 - by Bioz Stars,
2026-03
97/100 stars
Images
1) Product Images from "Anti-myeloma activity of the CXCR4 antagonist WZ811"
Article Title: Anti-myeloma activity of the CXCR4 antagonist WZ811
Journal: Journal of Molecular Medicine (Berlin, Germany)
doi: 10.1007/s00109-026-02650-4
Figure Legend Snippet: CXCR4 expression levels in MM. A The expression of CXCR4 at the protein level was analyzed in a panel of 14 MM cell lines (MM.1S, OPM-1, OPM-2, RPMI-S, RPMI-DOX6, RPMI-DOX40, RPMI-LR5, RPMI-MR20, JJN-3, KMS-11, L-363, OCI-My5, OCI-My7, and U266) by flow cytometry (FACS Canto II flow cytometer, Becton Dickinson), represented by histograms of CXCR4-BV421 positive expression (blue) compared to the negative Ig isotype control (grey), and B by western immunoblot analysis using anti-CXCR4 and anti-GAPDH (used as a loading control) antibodies. The fold change of the geometric mean of CXCR4 expression relative to the isotype fluorescent control is shown. The data are representative from three independent experiments. C CXCR4 expression at the transcriptional mRNA level was examined using RT-PCR, showing mRNA levels of CXCR4 in MM cell lines. The data are from three independent experiments and are presented as means ± standard deviation. D The representative 3D flow cytometry-based histograms depict CXCR4 expression on plasma cells (PC) in healthy donors (HD; black), monoclonal gammopathy of unknown significance (MGUS; light blue), smoldering MM (SMM; grey), newly diagnosed MM (NDMM; brown), and relapsed/refractory MM (RRMM; blue), compared to negative Ig isotype control (NEG; pink). The column bar graph shows the percentage of CXCR4 expression on normal PC (expressing CD138+/CD45+/CD38+) and non-PC of healthy donors (HD; n = 10), and malignant PC (expressing CD138+/CD45low/CD38++) and non-PC from primary bone marrow-derived cells of premalignant MGUS ( n = 15) and SMM ( n = 23), as well as active NDMM ( n = 39) and RMM ( n = 102) MM patients analyzed by flow cytometry and calculated using the Mann-Whitney U test, * p < 0.05 and **** p < 0.0001
Techniques Used: Expressing, Flow Cytometry, Control, Western Blot, Reverse Transcription Polymerase Chain Reaction, Standard Deviation, Clinical Proteomics, Derivative Assay, MANN-WHITNEY
Figure Legend Snippet: WZ811 decreases survival of MM cells. A MM cell lines (MM.1S, OPM-1, OPM-2, RPMI-S, RPMI-DOX6, RPMI-DOX40, RPMI-LR5, RPMI-MR20, JJN-3, KMS-11, L-363, OCI-My5, OCI-My7, and U266 cells) were exposed to indicated concentrations (0.625, 1.25, 2.5, 5, 10, 20, and 40 μM) of WZ811 for 48 h and 72 h. The cell survival was determined by MTT assay, and the EC 50 values of WZ811 were examined in MM cell lines for 48 h and 72 h using the CalcuSyn software. B Freshly sorted malignant bone marrow PC (expressing CD138+/CD45low/CD38++; n = 14) and tumor microenvironment cells (non-PCs; n = 14), both obtained from the same primary MM patient samples, were exposed to the indicated concentrations (1.25, 2.5, 5, 10, 20, and 40 μM) of WZ811 for 48 h. The cell survival was assessed by CellTiterGlo assay, and the EC 50 values of WZ811 in both PC and non-PC populations were determined for 48 h using the CalcuSyn software. If an exceptionally high EC 50 value was observed, it was reported as “n.a.” C Freshly isolated peripheral blood mononuclear cells (MNCs) from healthy donors (HD; n = 6) were exposed to indicated concentrations (0.625, 1.25, 2.5, 5, 10, 20, and 40 μM) of WZ811 for 48 h, and cell survival was assessed by MTT assay. The EC 50 values of WZ811 were determined in HD for 48 h using the CalcuSyn software. EC50 data are not presented due to exceptionally high values. Each treatment with a specific concentration of WZ811 was performed in triplicate. The presented data are mean ± standard deviation, expressed as survival/viability relative to untreated controls. EC 50 (half maximal effective concentration) is shown with lower and upper 95% confidence intervals (CI). D The median EC 50 values of WZ811 in MM cell lines, malignant PC, and non-PC of primary cells derived from MM patients, as well as MNCs of HD, were compared and calculated using One-way ANOVA on ranks followed by Kruskal-Wallis multiple comparison test, with *** p < 0.001
Techniques Used: MTT Assay, Software, Expressing, Isolation, Concentration Assay, Standard Deviation, Derivative Assay, Comparison
Figure Legend Snippet: WZ811 induces apoptosis and autophagy in MM cells. MM.1S, RPMI-S, and OPM-1 cells were treated with indicated concentrations (10, 20, 40, and 80 μM) of WZ811 for 72 h. A Representative flow cytometry-based dot plots showing the proportions of JC-1 aggregates versus JC-1 monomers in WZ811-treated MM.1S cells at 80 μM compared to control cells for 72 h. Decrease of mitochondrial membrane potential in MM cells after exposure to WZ811 was examined by staining with the fluorescent JC1 dye, indicating increased levels of JC-1 monomers, and analyzed by a FACS Canto II flow cytometer. B Representative flow cytometry-based dot plots showing the proportions of early apoptotic (Annexin V+/PI−), late apoptotic (Annexin V+/PI+/−), and necrotic (Annexin V+/PI+) cells in WZ811-treated MM.1S cells at 80 μM compared to control cells for 72 h. Induction of Annexin V+/Pi−, Annexin V+/Pi+/−, and Annexin V+/Pi+ cells was determined with Annexin V-FITC and Pi staining and analyzed by a FACS Canto II flow cytometer. The data are from three independent experiments and presented as means ± standard deviation. Significant differences between treatments and control were identified by one-way ANOVA followed by Dunnett’s multiple comparison test with * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Modulation of C apoptotic- and D autophagic-related regulation proteins was evaluated in MM cells after exposure to WZ811 and compared to control (DMSO-treated) cells by Western blot analysis. Western blot analyses were performed on whole cell lysates (20 μg of proteins/lane) using anti-caspase-3, -caspase-7, -caspase-8, -PARP, -Bax, -AIF, -Mcl-1, -Beclin-1, -LC3A/B, -SQSTM1/p62, -ATG3, -ATG7, -ATG5-12, -ATG16L1, and -GAPDH (serving as a loading control) antibodies. Data are representative of two independent experiments
Techniques Used: Flow Cytometry, Control, Membrane, Staining, Standard Deviation, Comparison, Western Blot
Figure Legend Snippet: WZ811 induces G0/G1 cell cycle arrest in MM cells. A Flow cytometry-based cell cycle analysis of control and WZ811-treated MM.1S cells at 80 μM for 72 h with the distribution of cells in G0/G1, S, and G2/M phase showing the representative data out of three experiments. MM.1S, RPMI-S, and OPM-1 cells were exposed to indicated concentrations (10, 20, 40, and 80 μM) of WZ811 for 72 h, and their cell cycle profiles were analyzed using propidium iodide (Pi) staining. The distribution of cells in G0/G1, S, and G2/M phase was measured by a FACS Canto II flow cytometer and analyzed with De Novo FCS Express software. The data are from three independent experiments and are presented as means ± standard deviation. Significant differences between treatments and control were identified by one-way ANOVA followed by Dunnett’s multiple comparison test with * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. B MM cell lines (MM.1S, RPMI-S, and OPM-1 cells) treated with WZ811 (10, 20, 40, and 80 μM) for 72 h were examined for changes in the levels of cell cycle regulatory and signaling molecules by western blot analysis. Western blot analyses of whole cell lysates (20 μg of proteins per lane) were immunoblotted using anti-mTOR, -p-mTOR, -ATM, -SIRT1, -c-Myc, -Notch1, -p-Cyclin B1, -Chk2, -Cdc2, -p-Cdc2, -histone H2AX (H2AX), -p-histone H2AX (p-H2AX), and -GAPDH (used as a loading control) antibodies. Results are representative of two independent experiments. C CXCR4 expression at the transcriptional mRNA level was examined after treatment with WZ811 (10, 20, 40, and 80 μM) for 6 h and 72 h in MM cell lines (MM.1S, RPMI-S, and OPM-1 cells) using RT-PCR analysis. Data are from three independent experiments and are presented as relative CXCR4 expression normalized to control ± standard deviation. D MM cell lines (MM.1S, RPMI-S, and OPM-1 cells) treated with WZ811 (10, 20, 40, and 80 μM) for 6 h were examined for changes in the expression levels of CXCR4 by western blot analysis. Western blot analyses of whole cell lysates (20 μg of proteins per lane) were immunoblotted using anti-CXCR4 and -GAPDH (used as a loading control) antibodies. Results are representative of two independent experiments
Techniques Used: Flow Cytometry, Cell Cycle Assay, Control, Staining, Software, Standard Deviation, Comparison, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction
Figure Legend Snippet: WZ811 decreases the side population fractions and increases the expression extracellular matrix proteins CXCL12, collagen IV and laminin in MM cells. A RPMI-S cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) and cultured either alone or in the presence of BMSC HS-5 cells. Non-viable MM (CFSE+/7-AAD+) and HS-5 stromal (CFSE-/7-AAD+) cells were identified by 7-aminoactinomycin D (7-AAD) staining (upper row). Side population (SP) cells were determined by low intracellular staining with Hoechst 33342 fluorescence dye, gating only on CFSE+/7-AAD− RPMI-S cells, either alone or in the presence of BMSC HS-5 cells (middle row). The SP cell fraction was examined after treatment with 80 μM WZ811 for 24 h in RPMI-S cells, either alone or in the presence of BMSC HS-5 cells (lower row), using a FACS Aria Special Sorter UV laser flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA). B OPM-1 and RPMI-S cells, stained with CFSE, either alone or in the presence of BMSC HS-5 cells, were exposed to the indicated concentrations (10, 20, 40, and 80 μM) of WZ811 for 24 and 72 h. The normalized proportion of the SP cell fraction was calculated relative to the control (untreated) MM cells, both alone and in co-culture with BMSC HS-5 cells. C The expression of CXCL12, collagen IV, and laminin at the protein level in MM.1S, RPMI-S, and OPM-1 cells, stained with CFSE and treated with different concentrations of WZ811 (5, 10, 20, 40, and 80 μM) for 72 h, either alone or in the presence of unstained BMSC HS-5 cells, was analyzed by flow cytometry. The data are from three independent experiments performed in triplicate and are presented as means ± standard deviation. Significant differences between treatments and control were identified by one-way ANOVA followed by Dunnett's multiple comparison test, with * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001
Techniques Used: Expressing, Staining, Cell Culture, Fluorescence, Flow Cytometry, Control, Co-Culture Assay, Standard Deviation, Comparison
Figure Legend Snippet: WZ811 decreases tumor burden in a mouse xenograft model of human MM in vivo. A MM.1S cells (2.5 × 10 6 cells in 200 μl PBS) were injected subcutaneously into CB17/SCID mice, and treatment was initiated when tumors became palpable. Tumor-bearing mice were randomly assigned into two groups (six mice per group) treated with WZ811 (diluted in water for injection with 10% DMSO and 5% Tween 80) at a concentration 40 mg/kg or vehicle control (water with 10% DMSO and 5% Tween 80), both administered by oral gavage (once a day for 5 consecutive days followed by 2 days off, and repeated for 5 weeks) in the xenograft MM mouse model. Tumor diameters were measured every 2–3 days with a caliper, and tumor volumes were calculated according to the formula of the volume of an ellipse: V = 4/3π × ( a /2) × ( b /2) 2 , where a and b correspond to the longest and shortest tumor diameter, respectively. Representative photograph shows vehicle-treated tumors (upper row) versus WZ811-treated tumors (lower row) at the end of experiment using Pro 12MP camera system. B The mice treated with WZ811 showed significant suppression of tumor growth compared to the mice treated with vehicle. Significant differences in the volume of the tumors between WZ811- and vehicle-treated mice were evaluated by two-way ANOVA followed by Tukey multiple comparison test with * p = 0.0108. The data are presented as the means ± standard deviation. C Body weights of mice were measured every 2–3 days and compared between WZ811-treated and vehicle-treated mice. D Kaplan-Meier analysis of overall survival showed a significant increase in the survival of WZ811-treated mice compared to vehicle-treated control mice, calculated by Kaplan-Meier log-rank test, with *** p = 0.0008. Numbers at risk (# at risk), hazard ratio (HR), and 95% confidence interval (CI) are shown
Techniques Used: In Vivo, Injection, Concentration Assay, Control, Comparison, Standard Deviation
Figure Legend Snippet: WZ811 in combination with anti-MM agents increases anti-MM activity in vitro. MM.1S, RPMI-S, and OPM-1 cells were exposed to the indicated concentrations (5, 10, and 20 μM) of WZ811 in combination with conventional agents: doxorubicin (DOX), dexamethasone (DEX) and melphalan (MEL), as well as novel agents: bortezomib (velcade; BTZ), carfilzomib (CFZ), lenalidomide (LEN), and pomalidomide (POM) anti-MM drugs for 24 h, 48 h and 72 h. Cell survival was then assessed by MTT assay, and combination effects were determined by the CalcuSyn software. A Fractions-affected (Fa; the ratio of the number of nonviable MM cells to the total number of MM cells) were visualized in a color-coded format and compared to treatment with each drug alone. B Isobologram analysis was performed to calculate the combination index (CI) for each combination by the Chou–Talalay method. The x-axis corresponds to the fractional effect at various combination doses in MM cells, and the y-axis represents the CI; CI < 1 indicates drug synergy, CI = 1 is considered additive, and CI > 1 indicates antagonism. All experiments were performed in triplicate. Data represent the median with interquartile range (IQR) of triplicate cultures
Techniques Used: Activity Assay, In Vitro, MTT Assay, Software